Equities

Seres Therapeutics Inc

Seres Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.7412
  • Today's Change0.009 / 1.28%
  • Shares traded895.16k
  • 1 Year change-33.82%
  • Beta2.0015
Data delayed at least 15 minutes, as of Nov 22 2024 17:17 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. The Company is engaged in developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). The Company is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The Company's clinical and nonclinical data across its programs support the development of live biotherapeutics to target the prevention and treatment of a broad swath of infections, and in inflammatory and immune diseases.

  • Revenue in USD (TTM)64.00k
  • Net income in USD-165.29m
  • Incorporated2010
  • Employees233.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Adverum Biotechnologies Inc1.00m-94.11m119.61m121.00--0.8299--119.61-6.03-6.030.05856.930.0046----8,264.46-43.66-36.39-50.24-39.04-----9,411.10-5,279.60----0.00----17.4324.18---0.0247--
Outlook Therapeutics Inc0.00-94.05m121.35m24.00---------8.12-8.120.00-3.570.00----0.00-205.48-214.69---1,843.48-------3,043.92---26.89--------10.70------
Ventyx Biosciences Inc0.00-152.52m122.33m75.00--0.4386-----2.37-2.370.003.940.00----0.00-48.98---52.21--------------0.00-------77.97------
Vigil Neuroscience Inc0.00-82.60m122.64m66.00--1.34-----2.07-2.070.002.230.00----0.00-56.88---66.15--------------0.00-------20.98------
Cidara Therapeutics Inc18.86m-123.53m122.96m69.00--1.06--6.52-26.06-25.943.7416.410.167--8.28273,304.30-109.42-65.23-169.41-154.3787.21---655.07-100.61----0.0055---0.8425--31.72--23.33--
Seres Therapeutics Inc64.00k-165.29m124.55m233.00--5.21--1,946.13-1.14-0.22710.00040.14050.0002----274.68-60.50-41.51-82.15-54.13-----258,259.40-170.14---20.450.00--1,672.2434.9154.54--32.72--
Pyxis Oncology Inc16.15m-57.36m124.88m54.00--0.8124--7.73-1.05-1.050.29772.590.0845----322,920.00-30.03---34.41--97.06---355.24------0.0008------38.87------
Repare Therapeutics Inc66.52m-84.05m126.26m179.00--0.7216--1.90-2.00-2.001.564.120.270--3.95371,642.50-34.11-23.40-40.73-26.37-----126.34-162.76----0.00---61.21---222.91--27.16--
Skye Bioscience Inc0.00-21.24m126.51m11.00--1.67-----0.8405-0.84050.002.500.00----0.00-43.73-232.67-54.60--------------0.00-------93.23--23.38--
Coherus Biosciences Inc304.34m-450.00k126.73m235.00----26.100.4164-0.0892-0.08922.60-0.76360.55912.941.58994,575.20-0.0827-21.43-0.1626-29.3244.7179.01-0.1479-36.561.09-3.921.50--21.89--18.46---18.37--
Cardiff Oncology Inc689.00k-43.01m127.83m31.00--2.47--185.54-0.9493-0.94930.01521.010.0091--1.6922,225.81-56.80-31.24-66.22-33.56-----6,238.17-7,819.23----0.00--26.425.22-7.07--157.91--
Fennec Pharmaceuticals Inc49.35m-1.13m129.48m36.00------2.62-0.1004-0.10041.75-0.18861.272.225.66---2.91-73.43-3.40-84.3293.52---2.30-383.287.640.59781.21--1,284.50--32.34------
TriSalus Life Sciences Inc26.89m-58.65m129.85m112.00------4.83-1.68-1.680.8963-0.67060.88121.236.75240,098.20-181.70---265.24--87.10---206.19--2.00-26.4317.43--49.31---26.51------
Data as of Nov 22 2024. Currency figures normalised to Seres Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

21.44%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Sep 202422.86m13.43%
The Vanguard Group, Inc.as of 30 Sep 20246.02m3.54%
BlackRock Fund Advisorsas of 30 Sep 20241.68m0.99%
Geode Capital Management LLCas of 30 Sep 20241.39m0.82%
Susquehanna Financial Group LLLPas of 30 Sep 20241.18m0.70%
Millennium Management LLCas of 30 Sep 20241.02m0.60%
Morgan Stanley & Co. LLCas of 30 Sep 2024756.70k0.45%
Charles Schwab Investment Management, Inc.as of 30 Sep 2024748.72k0.44%
Schonfeld Strategic Advisors LLCas of 30 Sep 2024433.90k0.26%
Bank Vontobel AGas of 30 Sep 2024394.83k0.23%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.